Petra Vayne-Bossert1,2, Banafsheh Afsharimani2, Phillip Good2,3, Paul Gray4,5, Janet Hardy6,7. 1. Readaptation and Palliative Care, University Hospital of Geneva, Geneva, Switzerland. 2. Palliative and Supportive Care, Mater Health Services Brisbane, Raymond Terrace, South Brisbane, 4101, QLD, Australia. 3. Palliative Care Services, St Vincent's Private Hospital Brisbane, Kangaroo Point, Australia. 4. School of Medicine, University of Queensland, St Lucia, Australia. 5. Department of Anaesthesia, Princess Alexandra Hospital, Brisbane, Australia. 6. Palliative and Supportive Care, Mater Health Services Brisbane, Raymond Terrace, South Brisbane, 4101, QLD, Australia. janet.hardy@mater.org.au. 7. School of Medicine, University of Queensland, St Lucia, Australia. janet.hardy@mater.org.au.
Abstract
PURPOSE: Pain is the most common symptom in cancer patients. Standard pain treatment according to the WHO three-step analgesic ladder provides effective pain management in approximately 70-90% of cancer patients. Refractory pain is defined as not responding to "standard" treatments. Interventional analgesic techniques can be used in an attempt to control refractory pain in patients in whom conventional analgesic strategies fail to provide effective pain relief or are intolerable due to severe adverse effects. This systematic review aims to provide the latest evidence on interventional refractory pain management in cancer patients. METHODS: Systematic literature search in Cochrane, EMBASE and PubMed including reviews and randomised controlled trials (RCTs) and non-randomised controlled trials in the absence of reviews. RESULTS: Neuraxial analgesia may play a role in refractory cancer pain management. Paravertebral blocks decrease the incidence of persistent post-surgical pain after breast cancer. Coeliac plexus blocks improve pain scores in refractory pancreatic cancer pain for up to 4 weeks after the intervention with fewer burdensome side effects as compared to opioids. Cordotomy has mainly been studied in mesothelioma, and the case series suggest possible benefit for pain at the expense of a relatively high risk of side effects. CONCLUSIONS: Overall, very few RCTs have been conducted on interventional pain techniques. In reality, it is very difficult to undertake large controlled trials for a number of reasons. Therefore, today's best evidence for practice may be from large case series of comparable patients with careful response and toxicity evaluation and follow-up.
PURPOSE:Pain is the most common symptom in cancerpatients. Standard pain treatment according to the WHO three-step analgesic ladder provides effective pain management in approximately 70-90% of cancerpatients. Refractory pain is defined as not responding to "standard" treatments. Interventional analgesic techniques can be used in an attempt to control refractory pain in patients in whom conventional analgesic strategies fail to provide effective pain relief or are intolerable due to severe adverse effects. This systematic review aims to provide the latest evidence on interventional refractory pain management in cancerpatients. METHODS: Systematic literature search in Cochrane, EMBASE and PubMed including reviews and randomised controlled trials (RCTs) and non-randomised controlled trials in the absence of reviews. RESULTS:Neuraxial analgesia may play a role in refractory cancer pain management. Paravertebral blocks decrease the incidence of persistent post-surgical pain after breast cancer. Coeliac plexus blocks improve pain scores in refractory pancreatic cancer pain for up to 4 weeks after the intervention with fewer burdensome side effects as compared to opioids. Cordotomy has mainly been studied in mesothelioma, and the case series suggest possible benefit for pain at the expense of a relatively high risk of side effects. CONCLUSIONS: Overall, very few RCTs have been conducted on interventional pain techniques. In reality, it is very difficult to undertake large controlled trials for a number of reasons. Therefore, today's best evidence for practice may be from large case series of comparable patients with careful response and toxicity evaluation and follow-up.
Authors: Jane C Ballantyne; Caroline Carwood; Anita Gupta; Michael I Bennett; Karen H Simpson; Karthikeyan Dhandapani; Louise Lynch; Ganesan Baranidharan Journal: Cochrane Database Syst Rev Date: 2013-10-25
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Laxmaiah Manchikanti; Frank J E Falco; Vijay Singh; Ramsin M Benyamin; Gabor B Racz; Standiford Helm; David L Caraway; Aaron K Calodney; Lee T Snook; Howard S Smith; Sanjeeva Gupta; Stephen P Ward; Jay S Grider; Joshua A Hirsch Journal: Pain Physician Date: 2013-04 Impact factor: 4.965
Authors: Dimitrios K Filippiadis; Steven Yevich; Frederic Deschamps; Jack W Jennings; Sean Tutton; Alexis Kelekis Journal: Curr Oncol Rep Date: 2019-11-25 Impact factor: 5.075
Authors: Michael I Bennett; Elon Eisenberg; Sam H Ahmedzai; Arun Bhaskar; Tony O'Brien; Sebastiano Mercadante; Nevenka Krčevski Škvarč; Kris Vissers; Stefan Wirz; Chris Wells; Bart Morlion Journal: Eur J Pain Date: 2019-01-06 Impact factor: 3.931